The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
1.45$ a min ago
US price on run up ⬆️
1.4$ now
Today released
https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-renalytix-ai-amidst-potential-acquisition-and-strong-market-prospects?utm_source=markets.businessinsider.com&utm_medium=referral
BTIG analyst Mark Massaro has reiterated their bullish stance on RNLX stock, giving a Buy rating on March 1.
Mark Massaro has given his Buy rating due to a combination of factors affecting Renalytix AI’s current position and future prospects. The company’s engagement in a formal sale process and the interest it has garnered from a well-capitalized strategic diagnostics company signal potential for acquisition, which is often a positive catalyst for a stock. Additionally, the company’s ongoing discussions to raise either equity or debt from both new and existing investors demonstrate efforts to strengthen its balance sheet. Massaro’s optimism is also based on the company’s solid execution of critical milestones in the past year, despite its relatively low cash reserves.
Massaro’s confidence in the stock is further buoyed by Renalytix AI’s sizable total addressable market, estimated to be over $13 billion, which suggests significant growth potential. Furthermore, the anticipation of increased mergers and acquisitions activity in the sector, as evidenced by recent deals, contributes to the positive outlook for Renalytix AI. The company also has several upcoming catalysts that could drive its value, including a potential acquisition, improvements to its financial position, and advancements in its flagship product, KidneyIntelX. The valuation of the company’s stock at a $3 price target is based on a multiple of future revenue estimates, taking into account an appropriate discount rate and share count.
In another report released on March 1, Stifel Nicolaus also maintained a Buy rating on the stock with a $5.00 price target.
Sale to other capitals are often a best practice in such situations. Not has to be a sale on the open market to unknown buyers
Any price prediction for the sales offer?
1.35$ and going
US movinv quick up - at 1.36$ now … 1h:15 to main session
Are games of those buying large at cheapest point … interest is massive in US
US - 5AM
Trading at range 1.4-1.8$ / 865K shares traded
Move between 20-50% up - was 1.65$ 5 min ago
Volume 500k shares transacted
Its 04:34 AM in New York
Went 30% up than down, now 15% up again. Its early hour - lets wait for volume
Expect 5$ today
Let me check
Yes could easy go to 5$ today in US
Yes but its 4AM … traffic is more from 6AM onwards … however often II buying early large volumes. Could be easy tens of millions dollar
In principal the productline enters first in US where healthcare pay 130B USD yearly around kidney issues. It will be well received as early test adopter to drive costs down. So mainly billions will be generated here and more savings in the health system.
1.32$ closing price
That can crazy go up today - US market more aware about opportunity than yesterday. We had big guys buying in US a lot yesterday.
Pre-Market (4:00-9:30 a.m. ET) or UK time 9AM - 2:30PM
But not many awake at 4AM normally
They moving shares into US as we speak. MMs are dry in US.
Yesterday 60M USD were traded. That will be fun today
Assume when US Kick in we get in Uk over £1